Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,973 | -16,516 | -11,155 | -7,642 | -3,362 |
| Depreciation Amortization | 808 | 2,909 | 2,136 | 1,543 | 707 |
| Accounts receivable | 4 | 141 | 231 | 140 | 143 |
| Other Working Capital | -969 | 28 | -160 | 401 | -557 |
| Other Operating Activity | -586 | -157 | -801 | -595 | -288 |
| Operating Cash Flow | $-5,717 | $-13,594 | $-9,748 | $-6,153 | $-3,357 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -117 | -960 | -781 | -538 | -296 |
| Net Acquisitions | N/A | -241 | -241 | -241 | -241 |
| Purchase Sale Intangibles | N/A | -2 | -2 | -2 | -2 |
| Other Investing Activity | -1 | -2 | -1 | -1 | -1 |
| Investing Cash Flow | $-117 | $-1,203 | $-1,023 | $-780 | $-538 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 0 | 3,862 | 3,862 | 827 | 690 |
| Financing Cash Flow | $0 | $3,862 | $3,862 | $827 | $690 |
| Exchange Rate Effect | 110 | -179 | -185 | 163 | 18 |
| Beginning Cash Position | 22,212 | 33,325 | 33,325 | 33,325 | 33,325 |
| End Cash Position | 16,488 | 22,212 | 26,230 | 27,382 | 30,137 |
| Net Cash Flow | $-5,724 | $-11,113 | $-7,095 | $-5,943 | $-3,188 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,717 | -13,594 | -9,748 | -6,153 | -3,357 |
| Capital Expenditure | -117 | -960 | -781 | -538 | -296 |
| Free Cash Flow | -5,834 | -14,554 | -10,529 | -6,691 | -3,653 |